指南与共识血栓与止血

美国血液学会2021指南:COVID-19患者血栓预防的抗凝使用

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.
指南 / 共识 · Blood Adv · 2021-01-01

美国血液学会(ASH)针对无确诊或疑似静脉血栓栓塞症(VTE)的COVID-19相关危重或急性疾病患者,制定了抗凝用于血栓预防的循证指南。指南采用GRADE方法,基于截至2020年8月19日的系统评价,形成2条有条件推荐,建议预防强度抗凝优于中间或治疗强度抗凝。推荐基于极低确定性证据,强调需高质量随机对照试验。

要点

  • 无确诊或疑似VTE的COVID-19危重或急性疾病患者,推荐预防强度抗凝。
  • 不建议采用中间强度或治疗强度抗凝用于血栓预防。
  • 推荐基于极低确定性证据,需随机对照试验验证。

核心结论

  • 对于无确诊或疑似VTE的COVID-19相关危重或急性疾病患者,ASH有条件推荐预防强度抗凝优于中间或治疗强度抗凝。

研究设计与样本

  • ASH组建多学科指南小组,包括3名患者代表,采用严格利益冲突管理策略。
  • 麦克马斯特大学GRADE中心支持指南制定,包括截至2020年8月19日的系统证据评价。

主要发现

  • 指南小组就2条推荐达成一致,均为有条件推荐。
  • 推荐基于极低确定性证据,强调需高质量随机对照试验比较不同抗凝强度。

关键数值与推荐

  • 推荐条款:对无确诊或疑似VTE的COVID-19相关危重或急性疾病患者,预防强度抗凝优于中间或治疗强度抗凝(有条件推荐,极低确定性证据)。

临床怎么用

  • 临床医生应对无确诊或疑似VTE的COVID-19危重或急性疾病患者使用预防强度抗凝进行血栓预防。
  • 不推荐常规使用中间或治疗强度抗凝用于此类患者的血栓预防。

局限性

  • 证据确定性极低,需高质量随机对照试验验证。
  • 指南将采用动态推荐方法,随着新证据出现进行更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronavirus disease 2019 (COVID-19)-related critical illness and acute illness are associated with a risk of venous thromboembolism (VTE). OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness and acute illness who do not have confirmed or suspected VTE. METHODS: ASH formed a multidisciplinary guideline panel and applied strict management strategies to minimize potential bias from conflicts of interest. The panel included 3 patient representatives. The McMaster University GRADE Centre supported the guideline-development process, including performing systematic evidence reviews (up to 19 August 2020). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 2 recommendations. The panel issued conditional recommendations in favor of prophylactic-intensity anticoagulation over intermediate-intensity or therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness or acute illness who do not have confirmed or suspected VTE. CONCLUSIONS: These recommendations were based on very low certainty in the evidence, underscoring the need for high-quality, randomized controlled trials comparing different intensities of anticoagulation. They will be updated using a living recommendation approach as new evidence becomes available.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 2021. PMID: 33560401. doi:10.1182/bloodadvances.2020003763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。